SKYE · Skye Bioscience, Inc. · Proposed Sales
$1.76
+0.03 (+1.99%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If adequate funds are not available to the Company when needed it will be required to curtail or perhaps cease operations which would, in turn, further raise substantial doubt about its ability to continue as a going concern. These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern within one year after the date that these financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$7.39M
Shares
4.43M
Volume · Oct 5
35.22K
Avg daily vol (30 sessions)
81.09K
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2024-11-15 | DHILLON PUNIT | Officer, Director | 100,693 | 2024-11-15 | Piper Sandler & Co Inc |
| 2024-11-15 | Diep Tuan Tu | Officer | 22,877 | 2024-11-15 | Piper Sandler & Co Inc |
| 2024-11-15 | Grayson Paul A. | Director | 86,804 | 2024-11-15 | Piper Sandler & Co Inc |
| 2024-11-15 | ARSENAULT KAITLYN | Officer | 57,084 | 2024-11-15 | Piper Sandler & Co Inc |
Showing 1–4 of 4 filings